Read More

MorphoSys Spokesperson Says “This Story Is Factually Wrong” In An Emailed Statement To Bloomberg News, In Response To STAT News’ Adam Feuerstein Article Entitled, “Why Novartis Is Going To Walk Away From Its Acquisition”

Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com) Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or

MOR

Read More

Specialty Chemicals Major Linde Shares Are Surging Today: What’s Going On?

Linde sees a surge in shares as Q4 FY23 sales hit $8.30 billion, beating consensus, with adjusted operating profit up 14% Y/Y to $2.3 billion and adjusted EPS of $3.59 surpassing expectations. CEO Sanjiv Lamba expresses confidence amidst uncertain geopolitical and macro environments, emphasizing Linde's strong position to capitalize on opportunities.

LIN

Read More

TotalEnergies Goes Both Ways: Fighting Emissions While Investing In Exploration

TotalEnergies (NYSE: TTE) climbs as it joins hands with ONGC to combat methane emissions in India, leveraging innovative AUSEA technology to align with the country's ambitious zero-emission goal by 2030. Also, it strengthens its offshore drilling portfolio by acquiring a majority stake in the Tungsten Explorer drillship through a partnership with Vantage Drilling.

TTE

Read More

Calibr-Skaggs Announces Expansion Of Option And License Agreement With AbbVie To Develop Novel Cell Therapies; AbbVie Will Pay Calibr-Skaggs An Upfront License Fee And Maintain Exclusive Access To Their Switchable Car-T Platform For A Term Of Upto 5-Ye…

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVieAbbVie also has the option to explore the

ABBV